Baxter International Inc., of Deerfield, Ill., said that patients in the twice-weekly prophylaxis arm of a pivotal phase III trial of its extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia, BAX 855, experienced a 95 percent reduction in median annualized bleed rate as compared to those in the on-demand arm (1.9 vs. 41.5, respectively).